Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
URGN
UroGen Pharma Ltd.
UGN-301 (anti-CTLA-4) places URGN in Immunology Therapeutics within oncology.
|
$983.11M |
$21.23
-9.54%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Directly focused on oncology therapeutics; Bicara's lead candidate is an antibody-based cancer therapy.
|
$979.40M |
$18.23
+10.08%
|
|
PLSE
Pulse Biosciences, Inc.
Pulse Biosciences develops nsPFA-based medical devices (e.g., CellFX platform) for non-thermal tissue ablation across soft tissue and cardiac indications.
|
$974.86M |
$14.56
-1.09%
|
|
NBTX
Nanobiotix S.A.
NBTXR3 is Nanobiotix's lead oncology therapy (hafnium oxide nanoparticle) used to enhance radiation therapy, fitting Biotech - Oncology.
|
$974.15M |
$20.87
+4.51%
|
|
PNTG
The Pennant Group, Inc.
Pennant's direct service offerings include Home Health and Hospice care across the post-acute continuum.
|
$972.23M |
$28.13
-3.33%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$958.91M |
$13.94
-1.10%
|
|
TBPH
Theravance Biopharma, Inc.
Ampreloxetine is an oral small-molecule therapeutic in Phase 3 (CYPRESS) for symptomatic nOH in MSA, representing a core TBPH pipeline asset.
|
$958.88M |
$19.02
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$948.91M |
$4.58
-7.58%
|
|
GHRS
GH Research PLC
GH Research's focus on neuropsychiatric drug development (CNS/psychiatric disorders) via 5-MeO-DMT therapies.
|
$931.06M |
$15.02
-3.41%
|
|
MEG
Montrose Environmental Group, Inc.
Laboratory testing and advisory services as part of Montrose's measurement and analysis offerings.
|
$929.09M |
$26.29
+2.10%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$919.51M |
$4.16
-3.03%
|
|
DAWN
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals markets and develops Oral Small Molecule Therapeutics (OJEMDA/tovorafenib) as a lead product.
|
$915.74M |
$9.16
-0.92%
|
|
INMD
InMode Ltd.
InMode's core business is medical devices and biometrics, with RF-based aesthetic platforms and related systems.
|
$913.36M |
$14.32
+0.46%
|
|
CDNA
CareDx, Inc
Directly provides Laboratory Testing & Advisory Services through its testing portfolio and diagnostic operations.
|
$911.78M |
$17.13
-0.52%
|
|
MDXG
MiMedx Group, Inc.
Directly manufactures and sells wound care devices and placental tissue allografts (EPIFIX, EPICORD, EPIEFFECT) used in wound healing.
|
$902.55M |
$6.09
-3.41%
|
|
CLB
Core Laboratories N.V.
CLB provides laboratory testing and advisory services via proprietary tracers and reservoir analysis capabilities.
|
$889.58M |
$18.98
+0.53%
|
|
ORIC
ORIC Pharmaceuticals, Inc.
ORIC develops oncology therapies (e.g., ORIC-944, ORIC-114, ORIC-533) targeting cancer resistance, placing it in Biotech - Oncology.
|
$888.68M |
$9.05
+7.16%
|
|
IOVA
Iovance Biotherapeutics, Inc.
Company's core offering is cell therapy (TIL) with autologous lymphocytes, including next-generation pipeline programs, defining the Biotech - Cell Therapy category.
|
$886.54M |
$2.45
-6.13%
|
|
ARVN
Arvinas, Inc.
Lead program ARV-471 (vepdegestrant) is an oncology-focused asset, reflecting Arvinas' core business in cancer therapeutics and PROTAC technology.
|
$886.15M |
$12.21
+0.29%
|
|
SIBN
SI-BONE, Inc.
SI-BONE operates as a medical device company that designs, develops and sells orthopedic implants and related medical devices.
|
$881.80M |
$20.31
-2.73%
|
|
MATW
Matthews International Corporation
Memorialization segment includes embalming chemicals and funeral supplies (memorialization products).
|
$879.39M |
$28.57
+2.27%
|
|
BBNX
Beta Bionics, Inc.
Core product is a medical device (iLet Bionic Pancreas) and related biometrics in diabetes care.
|
$875.49M |
$21.01
-34.32%
|
|
CBLL
CeriBell, Inc.
Ceribell's core product is a point-of-care diagnostic EEG system (diagnostic equipment).
|
$855.37M |
$23.32
+1.08%
|
|
GERN
Geron Corporation
Geron directly develops and commercializes RYTELO (imetelstat), an oncology therapeutic indicated for lower-risk MDS.
|
$854.94M |
$1.37
|
|
FLGT
Fulgent Genetics, Inc.
Company operates clinical lab chains providing diagnostic testing.
|
$852.46M |
$27.86
-0.11%
|
|
JANX
Janux Therapeutics, Inc.
Company focuses on tumor-activated oncology therapies (TRACTr/TRACIr), placing JANX squarely in Biotech - Oncology.
|
$850.93M |
$14.03
+0.86%
|
|
KALV
KalVista Pharmaceuticals, Inc.
EKTERLY (sebetralstat) is KalVista's lead asset and is an oral small-molecule therapeutic for acute hereditary angioedema, directly reflecting their product category.
|
$839.22M |
$16.99
+7.40%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
Company focuses on oncology therapeutics, positioning it within Biotech - Oncology.
|
$832.47M |
$20.55
+4.74%
|
|
KURA
Kura Oncology, Inc.
Kura's core business is oncology-focused biotechnology developing ziftomenib and related menin inhibitors for AML, placing it in Biotech - Oncology.
|
$816.76M |
$9.40
-1.52%
|
|
VIR
Vir Biotechnology, Inc.
PRO-XTEN masking platform represents a drug delivery platform intended to improve safety and therapeutic index.
|
$812.66M |
$5.86
-1.60%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$801.43M |
$9.93
+1.85%
|
Showing page 15 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
